These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25221952)

  • 1. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
    Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
    PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
    Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
    Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
    Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
    Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
    Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
    Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
    Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
    Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
    Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
    Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
    Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
    Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
    Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
    Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
    Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
    Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.